JPMorgan analyst Anupam Rama lowered the firm’s price target on Sage Therapeutics to $18 from $23 and keeps an Overweight rating on the shares. The analyst updated models in the SMID-cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $23 from $28 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- SAGE Therapeutics Shareholders Back Governance and Incentives
- Sage Therapeutics data ‘head-scratcher and inconclusive,’ says Citi
- Baird views Sage’s SURVEYOR as ‘failed phase 2a study’